The median survival of glioblastoma patients is∼ 12 months. However, 3–5% of the patients
survives for more than 3 years and are referred to as long-term survivors. The clinical and …

An intact immune system is essential to prevent the development and progression of
neoplastic cells in a process termed immune surveillance. During this process the innate …

Malignant gliomas are the most frequently occurring, devastating primary brain tumors, and
are coupled with a poor survival rate. Despite the fact that complete neurosurgical resection …

Accurate pathological diagnosis is crucial for optimal management of patients with cancer.
For the approximately 100 known tumour types of the central nervous system …

WHO grading of human brain tumors extends beyond a strictly histological grading system
by providing a basis predictive for the clinical behavior of the respective neoplasm. For …

Purpose The prognostic value of genetic alterations characteristic of glioblastoma in patients
treated according to present standards of care is unclear. Patients and Methods Three …

Background Standard therapy for glioblastoma includes surgery, radiotherapy, and
temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate …

Abstract The base 5-hydroxymethylcytosine (5hmC) was recently identified as an oxidation
product of 5-methylcytosine in mammalian DNA. Here, using sensitive and quantitative …

Purpose: To evaluate response rate, response duration, overall survival (OS), and toxicity in
primary CNS lymphoma (PCNSL) after systemic and intraventricular chemotherapy with …

The benefit of cytoreductive surgery for glioblastoma multiforme (GBM) is unclear, and
selection bias in past series has been observed. The 5-aminolevulinic acid (ALA) study …